One of the reasons for Zel’s national reputation as a leader in skin and laser care is its Clinical Research Department. This department conducts numerous clinical trials (scientific studies of how a new medicine or treatment works in people). Such studies enable doctors to find better ways to prevent, detect, diagnose, control and treat medical conditions and illnesses.
Brian Zelickson, MD, Zel’s medical director, is the principal investigator for many of our studies. Assisting Dr. Zelickson on these projects is Zel’s
research coordinator, Irmina Wallander, and members of our clinical staff.
OUR RESEARCH BENEFITS OUR CLIENTS
Findings from the clinical trials conducted at Zel often lead to new and improved treatments. After the studies are completed, the results are presented at national medical meetings and frequently published in peer–review medical journals.
But the research we conduct at Zel benefits our clients even more directly. Because of these studies, we are able to obtain new, effective technologies — and to develop experience using them — before they become available to the general public.
Clinical trials conducted at Zel have focused on a wide variety of state–of–the–art treatments, including ones for acne, hair removal, facial blood vessels, leg veins, wrinkles and psoriasis.
Zel’s Clinical Research Department is continually conducting new studies that require clinical research subjects. You can read about these studies here. If you are interested in participating in clinical research at Zel and would like more information, please contact the research coordinator by phone at (952) 746–1017 or by email at firstname.lastname@example.org. You may also fill out a research volunteer form to be entered into the general database for clinical trials being conducted now or in the future.
MEDICAL ADVISORY BOARD:
Dr. Brian Zelickson is one of the very few physicians in the world who participates in developing new energy based medical technology for Dermatology at Zel Skin & Laser Specialists.
We have worked with a majority of the companies in this field including Candela, Thermage, Reliant, Palomar, Sciton, Lumenis, Syneron, Gel–Del, Wave Rx. Ulthera, Eleme, and Zeltiq.
We have received research grants and discounts on equipment. Dr. Zelickson serves on the Medical Advisory Board of Zeltiq, Lumenis and Candela. Dr. Zelickson has also received stock options from Zeltiq as part of his Medical Board compensation. Dr. Zelickson has patents licensed by Candela and Harvard’s Massachusetts General Hospital.